Prescribing
Information

This site is intended for US
healthcare professionals only.

Indication

ICLUSIG® (ponatinib) is a kinase inhibitor indicated for the:

  • Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.
  • Treatment of adult patients with T315I-positive chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL.

Limitation of use:
ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase CML.